Impact of Computerized Decision Support for ANTIBIOtic Prescription in Cancer Patients With Febrile NEutropenia in the Emergency Department on Treatment Failure. (ANTIBIONEED)
Impact of Computerized Decision Support for ANTIBIOtic Prescription in Cancer Patients With Febrile NEutropenia in the Emergency Department on Treatment Failure. A Randomized Cluster-controlled Trial.
Treatment of patients with febrile neutropenia (FN) attending Emergency Departments (EDs) relies on rapid antibiotic initiation in order to control a presumed infection. The choice of initial antibiotics is empirical and depends on patient's prior colonization or infection by multi-drug resistant pathogens (MDRPs) and risk stratification. Stratification of high-risk patients needing broad-spectrum antibiotics is debated. Thus, for non-specialist physicians, this choice may be challenging, leading to inappropriate initial antimicrobial regimens, potential risks for the patient and higher costs. Furthermore, international guidelines recommended to develop antibiotic stewardship programs and promoted an initial strategy based on escalation or de-escalation approaches, with early reassessment depending on patients' clinical course and microbiological results. Nevertheless, this interesting strategy may increase the level of complexity for the choice of the initial antibiotic regimen by non-specialist emergency physicians who are often the first prescribers in this context.
We developed an interactive computerized decision support app (CDSA) for initial antibiotic prescription and early revaluation in patients with FN. The first goal of this app is to assist non-specialized physicians in choosing initial antimicrobial regimen for patients with FN when they attend EDs. It uses an interactive algorithm based on international guidelines that takes into account patients' medical history and characteristics. Secondly, the app is also designed to propose an algorithm of antibiotic revaluation at day 3-4 for hospitalized patients, depending on patient clinical course, and biological and microbiological results. The revaluation suggests antimicrobial modification (escalation or de-escalation) or discontinuation and stopping rules with recommended duration of therapy also based on international guidelines.
We hypothesize that such a CDSA may improve the adherence to guidelines for the choice of initial antibiotic regimen for FN in the ED, favour early antibiotic reassessment for hospitalized patients, both decreasing the risk of treatment failure.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Olivier Peyrony
- Telefoonnummer: +33142494804
- E-mail: olivier.peyrony@aphp.fr
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- age ≥ 18 years;
- reported or observed fever at arrival at the ED (≥38.3° C on one occasion or ≥38°C on two or more occasions within 1 h);
- chemotherapy-induced neutropenia (absolute neutrophil count ≤500/mm3 or ≤1000/mm3 and anticipated to decrease to fewer than 500/mm3 within 24 to 48 h).
Exclusion Criteria:
- refusal to participate;
- prior inclusion in the study for a previous episode of FN;
- any intravenous antibiotic administration during the preceding 72 h;
- renal failure requiring renal replacement therapy or with an estimated creatinine clearance of less than 20 ml/min;
- palliative status with life expectancy of less than three days;
- pregnancy, absence of health insurance, mental deficiency or inability to understand informed consent, no French speaking;
- patient with a microbiological documented infection when arriving at the ED (e.g. positive blood culture).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Control Group
As routine care, the choice of the initial antibiotic regimen will be let to the discretion of the emergency physician.
|
The choice of the initial antibiotic regimen will be let to the discretion of the emergency physician
|
|
Experimenteel: computerized decision support app (CDSA) Group
|
Implementation of an Computerized Decision support app (CDSA) : physician will use this app to help him in the antibiotic choice.
This app is an interactive algorithm based on international guidelines that takes into account patients' medical history and characteristics.
Secondly, the application is also designed to propose an algorithm of antibiotic revaluation at day 3 for hospitalized patients, depending on patient clinical course, and biological and microbiological results.
The revaluation suggests antimicrobial modification (escalation or de-escalation) or discontinuation and stopping rules with recommended duration of therapy also based on international guidelines.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Treatment failure
Tijdsspanne: 7 days following inclusion
|
Treatment failure will be defined by any escalation of the assigned empirical initial antibiotic treatment (e.g. adjunction of aminoglycoside, glycopeptide or other anti-gram positive or any broadening of the beta-lactam spectrum) during the 7 days following inclusion, in relation with at least one of the following reasons:
|
7 days following inclusion
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of initial antibiotic regimen adhering to the international guidelines
Tijdsspanne: at inclusion
|
at inclusion
|
|
|
Time to antibiotic initiation from patient triage at the emergency department (minutes)
Tijdsspanne: at inclusion
|
at inclusion
|
|
|
Number of revaluations of initial antibiotic regimen at day 3 depending on patient clinical course and microbiological results;
Tijdsspanne: at 3 days
|
at 3 days
|
|
|
Number of antimicrobial spectrum reductions
Tijdsspanne: at 3 days
|
at 3 days
|
|
|
Number of antibiotic regimens with carbapenems, aminoglycosides or glycopeptides
Tijdsspanne: at inclusion
|
at inclusion
|
|
|
Number of days of Carbapenems, aminoglycosides and glycopeptides therapy
Tijdsspanne: up to 3 months
|
up to 3 months
|
|
|
Number of super-infections
Tijdsspanne: up to 3 months
|
A super-infection will be defined as new, persistent or worsening symptoms and/or signs of infection associated with the isolation of a new pathogen (different, or different susceptibilities) or the development of a new site of infection;
|
up to 3 months
|
|
Number of super-infections due to clostridium difficile
Tijdsspanne: up to 3 months
|
up to 3 months
|
|
|
Number of colonization
Tijdsspanne: up to 3 months
|
Colonization will be defined as isolation during or after therapy of Gram-negative bacteria resistant to the beta-lactam included in the empirical regimen, without symptoms or signs of infection
|
up to 3 months
|
|
Number of episodes of nephrotoxicity
Tijdsspanne: up to 3 months
|
up to 3 months
|
|
|
Number of episodes of other toxicities
Tijdsspanne: up to 3 months
|
Toxicities will be defined according to the common terminology criteria for adverse events
|
up to 3 months
|
|
Occurrence of any complication during hospital stay or follow-up
Tijdsspanne: up to 3 months
|
up to 3 months
|
|
|
Number of re-hospitalizations due to a complication related to the initial infection
Tijdsspanne: within 7 days of discharge
|
within 7 days of discharge
|
|
|
Antibiotic treatment duration
Tijdsspanne: up to 3 months
|
up to 3 months
|
|
|
Length of hospital stay
Tijdsspanne: up to 3 months
|
up to 3 months
|
|
|
Total 3-month costs
Tijdsspanne: at 3 months
|
at 3 months
|
|
|
Number of deaths related to infection
Tijdsspanne: at 3 months
|
Death related to infections will be defined according to the physician in charge of the patient
|
at 3 months
|
|
Number of in-hospital death
Tijdsspanne: up to 3 months
|
up to 3 months
|
|
|
Survival status
Tijdsspanne: at day 90
|
at day 90
|
|
|
Health related quality of life
Tijdsspanne: at inclusion
|
Quality of life will be assessed using the EQ5D5L scale.
The EQ5D5L scale is composed of two parts: a descriptive system and the EQ Visual Analog Scale (EQ VAS).
The descriptive system has five dimensions.
Each dimension has five levels: no problems, mild problems, moderate problems, severe problems and extreme problems.
The descriptive system ranges from 1 to 25, the higher the score the worse the quality of life.
The score goes from VAS 0 to 100, the higher the VAS score the better the quality of life.
|
at inclusion
|
|
Health related quality of life.
Tijdsspanne: at day 30
|
Quality of life will be assessed using the EQ5D5L scale.
The EQ5D5L scale is composed of two parts: a descriptive system and the EQ Visual Analog Scale (EQ VAS).
The descriptive system has five dimensions.
Each dimension has five levels: no problems, mild problems, moderate problems, severe problems and extreme problems.
The descriptive system ranges from 1 to 25, the higher the score the worse the quality of life.
The score goes from VAS 0 to 100, the higher the VAS score the better the quality of life.
|
at day 30
|
|
Health related quality of life.
Tijdsspanne: at 3 months
|
Quality of life will be assessed using the EQ5D5L scale.
The EQ5D5L scale is composed of two parts: a descriptive system and the EQ Visual Analog Scale (EQ VAS).
The descriptive system has five dimensions.
Each dimension has five levels: no problems, mild problems, moderate problems, severe problems and extreme problems.
The descriptive system ranges from 1 to 25, the higher the score the worse the quality of life.
The score goes from VAS 0 to 100, the higher the VAS score the better the quality of life.
|
at 3 months
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- APHP210357
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .